Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

BrainStorm to Present at the 40th Annual Canaccord

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 112
Posts 24,633
Boards Moderated 6
Alias Born 02/07/04
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/27/2020 6:05:32 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/1/2020 4:53:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2020 4:16:53 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/25/2020 4:15:36 PM
Brainstorm Announces Grant of a New Japanese Patent for NurOwn® PR Newswire (US) - 9/16/2020 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2020 4:08:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:06:53 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/10/2020 6:07:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 7:01:27 AM
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update PR Newswire (US) - 8/5/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 5:11:22 PM
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update PR Newswire (US) - 7/27/2020 7:58:00 AM
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:16:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:10:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:05:43 PM
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire (US) - 7/8/2020 5:31:00 AM
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire (US) - 7/2/2020 6:49:00 AM
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire (US) - 7/1/2020 8:50:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/26/2020 5:02:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2020 5:01:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/26/2020 5:01:04 PM
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire (US) - 6/24/2020 7:00:00 AM
BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire Inc. - 6/15/2020 9:00:10 AM
BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire (US) - 6/11/2020 7:28:00 AM
midastouch017   Monday, 08/10/20 07:39:15 AM
Re: None
Post # of 2834 
BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13, 2020. Company management will also be available for 1on1 meetings with institutional investors via video conference on the day of the presentation. To request a meeting, please contact your representative at Canaccord Genuity.

Participants can view the presentation via the event link and those unable to join will have access to an archived link on the Company's Events and Presentation webpage after the conclusion of the conference.

Event: 40th Annual Canaccord Genuity Growth Conference
Time: August 13, 2020 @ 3:30pm ET
Webcast: https://bit.ly/3fFxqPr

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at www.brainstorm-cell.com

CONTACTS
Investor Relations:
Preetam Shah, MBA, PhD
Chief Financial Officer
BrainStorm Cell Therapeutics Inc.
Phone: + 1.862.397.1860
pshah@brainstorm-cell.com

Corey Davis Ph.D.
LifeSci Advisors, LLC
Phone: +1 646-465-1138
cdavis@lifesciadvisors.com

Media:
Paul Tyahla
SmithSolve
Phone: + 1.973.713.3768
Paul.tyahla@smithsolve.com
SOURCE Brainstorm Cell Therapeutics Inc

https://finance.yahoo.com/news/brainstorm-present-40th-annual-canaccord-113000017.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences